Aizhan Tastanova

Biochemistry, Genetics and Molecular Biology · Life Sciences

12h-index432citations174works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(78), Computational Drug Discovery Methods(28), Immunotherapy and Immune Responses(23), CAR-T cell therapy research(14), Ferroptosis and cancer prognosis(12)

Publications174 total

Transcriptional memory states of malignant cutaneous T-cell lymphoma cells inform targeted therapy
Zenodo (CERN European Organization for Nuclear Research)·2026Open Access
Transcriptional memory states of malignant cutaneous T-cell lymphoma cells inform targeted therapy
Zenodo (CERN European Organization for Nuclear Research)·2026Open Access
Suppl. Figure S3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S10 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl Figure S4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S13 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S12 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S14 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S15 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl Figure S11 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl. Figure S8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
Suppl.Figure S16 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
2025Open Access
page 1 of 9Next →

Frequent Co-authors

Mitchell P. Levesque(41), Phil F. Cheng(35), Reinhard Dummer(32), Zsolt Balázs(31), Patrick Turko(31), Michael Krauthammer(31), Corinne I. Stoffel(29), Andreas Dzung(29), Pål Johansen(28), Annalisa Saltari(28), Ossia M. Eichhoff(26), Jan Käsler(26), Luzia Briker(26), Gergely Karsai(26), Nina Zila(26), Verena Paulitschke(26), Alexander Leitner(26), Andrea Bileck(26), Nicola Zamboni(26), Anja Irmisch(26)